CG Labz
Peptide Library / Metabolic / Weight Management

Tirzepatide

GIP/GLP-1 Dual Agonist

Tirzepatide Research Protocol & Titration Reference

Complete Research Guide 5 min read5 peer-reviewed references

Quickstart Overview

Tirzepatide is a 39-amino-acid dual GIP and GLP-1 receptor agonist built on the GIP backbone with a C-20 fatty diacid moiety. It is the first 'twincretin' to reach clinical use and produced the largest weight reductions of any approved peptide in the SURMOUNT programme.

Reconstitution
Add 2.0 mL bacteriostatic water to a 10 mg vial → 5 mg/mL
Clinical Titration
2.5 mg → 5 → 7.5 → 10 → 12.5 → 15 mg (4-week steps)
Measuring Reference
At 5 mg/mL: 2.5 mg = 0.5 mL = 50 units
Frequency
Once weekly
Half-life
≈ 5 days (120 h)
Route
Subcutaneous

Scientific Data

Molecular Formula
—
Molecular Weight
4813.53 Da
Sequence
Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS
Sequence Length
43
CAS
Research compound
Peptide Family
Twincretin
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 10 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
5.00 mg/mL
Draw Volume
0.500 mL
Syringe Units
50.0 U
Doses / Vial
4

Units assume a U-100 insulin syringe (100 units = 1 mL). Higher doses mean larger volumes — consider 10 mg/mL (1.0 mL water per 10 mg) for doses ≥ 7.5 mg.

Frequency: Once weekly

Reconstitution Steps

  1. 1Bring vial to room temperature; swab stoppers.
  2. 2Add bacteriostatic water slowly down the glass wall.
  3. 3Swirl gently until clear.
  4. 4Label and refrigerate.

Supplies Needed

Planning example for the first 16 weeks of titration (2.5 → 5 → 7.5 → 10 mg).

Peptide (10 mg vials)
16 weeks = 100 mg total = 10 vials
Bacteriostatic Water
One 30 mL vial
Syringes (U-100, 1 mL)
16
Alcohol Swabs
2 per administration

Protocol Overview

Goal
Model dual-incretin effects on body weight, glycaemia and cardiometabolic markers.
Schedule
Weekly, 4-week titration steps.
Dose Range
2.5 mg (initiation) to 15 mg (maximum).
Maintenance
5, 10 or 15 mg depending on response and tolerability.

Dosing Protocol

Weeks 1–4
2.5 mg weekly (initiation)
Weeks 5–8
5 mg weekly
Weeks 9–12
7.5 mg weekly
Weeks 13–16
10 mg weekly
Weeks 17–24
12.5 mg → 15 mg as tolerated
Timing
Same day weekly; with or without food; missed dose within 4 days

Storage Instructions

Lyophilized
−20 °C long term
Reconstituted
2–8 °C, use within 30 days
Room temperature
Pen products tolerate ≤ 30 °C for up to 21 days
Light
Protect from light

Important Notes

  • GI adverse events are comparable to or slightly lower than semaglutide at equivalent efficacy, attributed to GIP's anti-emetic signalling.
  • Same rodent thyroid C-cell boxed warning class as other incretins.
  • Greater reductions in triglycerides and liver fat than GLP-1 mono-agonists.
  • Lean-mass preservation remains a research focus; ~25% of weight lost is lean tissue in body-composition substudies.

How This Works

Tirzepatide binds the GIP receptor with affinity equal to native GIP and the GLP-1 receptor with roughly 5-fold lower affinity than native GLP-1, with biased signalling toward cAMP over β-arrestin recruitment. GLP-1 agonism drives glucose-dependent insulin release, glucagon suppression, delayed gastric emptying and central satiety. GIP agonism adds adipose-tissue insulin sensitisation, improved lipid buffering, and central effects that appear to blunt nausea. The combination produced 20.9% mean weight loss at 15 mg in SURMOUNT-1 and HbA1c reductions up to 2.4% in SURPASS.

Potential Benefits & Side Effects

Reported in research
  • ≈ 21% mean body-weight loss at 15 mg over 72 weeks (SURMOUNT-1)
  • HbA1c reduction of 1.9–2.4% (SURPASS programme)
  • Superior weight loss vs semaglutide in head-to-head SURMOUNT-5
  • Marked reductions in liver fat, triglycerides and visceral adiposity
  • Improvement in obstructive sleep apnoea (SURMOUNT-OSA)
  • Heart-failure outcome benefits (SUMMIT)
Possible considerations
  • Nausea (31%), diarrhoea (23%), vomiting (12%), constipation (17%) at 15 mg
  • Decreased appetite, dyspepsia, abdominal pain
  • Injection-site reactions, fatigue, hair loss
  • Gallbladder events; rare pancreatitis
  • Hypoglycaemia with concurrent insulin/sulfonylurea

Lifestyle Factors

  • Protein ≥ 1.6 g/kg and progressive resistance training to limit lean-mass loss
  • Smaller meals; stop eating at first satiety signal
  • Hydration and fibre intake to offset constipation
  • Monitor for rapid-weight-loss effects: gallstones, hair shedding, fatigue

Injection Technique

  1. 1Subcutaneous abdomen, thigh or upper arm; rotate weekly.
  2. 2Volumes above 0.5 mL benefit from slow 10-second injection.
  3. 390° insertion into pinched fold; hold 5–10 s after plunger depression.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] New England Journal of Medicine
    Jastreboff A.M. et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).
    View Source
  2. [2] New England Journal of Medicine
    Frías J.P. et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2).
    View Source
  3. [3] New England Journal of Medicine
    Aronne L.J. et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).
    View Source
  4. [4] Molecular Metabolism
    Coskun T. et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    View Source
  5. [5] New England Journal of Medicine
    Malhotra A. et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA).
    View Source